­
­
­
­

Inventi Impact - Pharm Tech

Patent Watch

  • Process for the preparation of crystalline perindopril

    The present invention relates to a new process for the preparation of crystalline perindopril. The present invention also relates to new alkyl ammonium salts of perindopril and the processes for the preparation thereof.

  • Haemostatic sprays and compositions

    The present invention is directed to a powder delivery system containing a composition comprising gelatin or collagen powder having a mean particle size of at least 10 .mu.m. The gelatin or collagen powder is typically in dry form, i.e. no liquid components and/or propellants are added to the composition. The present invention is also directed to an improved powder delivery system which contains a protective structure, such as a skirt, located close to the orifice of the delivery system. In a further aspect, the present invention is directed to gelatin- or collagen-based compositions useful in hemostatic applications. In a further aspect of the invention the powder delivery system comprises gelatin or collagen powder in a dry form ready to use. Further the powder delivery system in a dry form might comprise an agent incompatible with moisture and/or water.

  • Combinations for the treatment of immunoinflammatory disorders

    The invention features pharmaceutical compositions that include dipyridamole and a corticosteroid.

  • Methods and compositions for the treatment of gastrointestinal disorders

    The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

  • Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors

    The present invention includes composition and methods for making and using a combinatorial library to identify modified thioaptamers that bind to, and affect the immune response of a host animal, transcription factors such as IL-6, NF-.kappa.B, AP-1 and the like. Composition and methods are also provided for the treatment of viral infections, as well as, vaccines and vaccine adjuvants are provided that modify host immune responses.

  • Sustained-release, oral pharmaceutical forms of formulation

    A sustained-release, oral pharmaceutical formulation of tramadol comprising a compound formed in situ of tramadol or its salt and a pharmaceutically acceptable acidic substance. The compound formed in situ has a desired water solubility. Also provided are methods of treatment using the pharmaceutical formulations. Method for preparing such formulations are also provided. The preparation method comprises repeatedly mixing tramadol or its salt with the acidic substance, and moistening the mixture and formulating the mixture under an energy input, such as heat or pressure. Optionally, drying, repeated granulating, extrudation and pelleting may also be included.

  • Skin-contacting-adhesive free dressing

    A dressing having a flexible sleeve shaped to accommodate a substantially cylindrical body portion, the sleeve having a lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means which attaches two peripheral portions to each other without those portions being circumferentially adhered to the sleeve portion.

  • Nicotinamide derivatives

    The present invention relates to compounds of formula (I) ##STR00001## and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  • Process for making a low molecular weight gelatine hydrolysate

    The present invention provides a process to make a gelatine hydrolysate, a gelatine hydrolysate, and gelatine compositions including gelatine hydrolysates. More specifically, the invention provides gelatine compositions having a reduced tendency to cross-link and improved dissolution properties.

  • Enamel matrix protein composition for treatment of systemic inflammatory response

    The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin, for the manufacture of a pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli, i.e. wherein at least a part of said mammal's immune system is stimulated non-discriminatingly, reacts hypersensitively to said immunogen, or fails to react to said stimuli. Said condition can typically either be systemic or local, such as a systemic and/or post-traumatic whole-body inflammation or an autoimmune disease.

  • Sustained-release, oral pharmaceutical formulations and methods of making and using same

    A sustained-release, oral pharmaceutical formulation of tramadol comprising a compound formed in situ of tramadol or a tramadol salt and a pharmaceutically acceptable acidic substance. The compound formed in situ has a desired water solubility. Also provided are methods of treatment using the pharmaceutical formulations. Method for preparing such formulations are also provided. The preparation method comprises repeatedly mixing tramadol or its salt with the acidic substance, and moistening the mixture and formulating the mixture under an energy input, such as heat or pressure. Optionally, drying, repeated granulating, extrudation and pelleting may also be included.

  • Media compositions for eluting compounds from matrices and methods for making and using them

    Embodiments of the invention provide to apparatuses and media used in drug elution studies and methods for making and using them. One embodiment of the invention is a drug elution method that can be used for in-vitro studies of a matrix impregnated with a compound such as a drug blended polymer matrix. Such methods and materials can be used for example to assess and control the manufacturing process variability of drug eluting implantable devices such as cardiac leads.

  • Pharmaceutical formulation

    The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

  • High delivery rates for lipid based drug formulations, and methods of treatment thereof

    Provided is a method of preparing lipid based drug formulations with low lipid/drug ratios using coacervation techniques. Also provided are methods of delivering such lipid based drug formulations at high delivery rates, and methods of treating patients with pulmonary diseases comprising administering such lipid based drug formulations.

  • Stabilised solid drug dispersions in an organic carrier and a process for preparing the same

    New solid drug dispersions are described in which a drug is present in amorphous form and dispersed within the particles of an organic carrier selected from cross-linked polymers and/or complexing agents. These dispersions are obtainable by mixing the drug and the carrier and applying an oscillating electromagnetic field in the microwave region according to a specific heating cycle wherein the drug-carrier mixture is heated at a temperature higher than the melting point of the drug for at least 5 minutes.

  • Method of selling dosage forms without a prescription

    The invention features a method of selling dosage forms without a prescription. In accordance with one aspect of the invention, the dosage forms are sold in a container displayed on a retail shelf without outer secondary packaging. The container preferably is made of a material through which the dosage forms are visible. In accordance with another aspect of the invention, the container has at least one substantially flat side wall and is laid on a retail display shelf on its substantially flat side wall. The container may be formed to have only one plane of symmetry. At least one of the side walls of the container may be formed to facilitate gripping of the container.

  • Pharmaceutical preparation comprising an active dispersed on a matrix

    The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.

  • Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient

    Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.

  • Use of L-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use

    The use of L-carnitine and its alkanoyl derivatives, optionally in the form of a pharmaceutically acceptable salt, as osmotic agents in the preparation of solutions for medical use, particularly for peritoneal dialysis, is described.

  • Hydrophilic/lipophilic polymeric matrix dosage formulation

    An oral dosage form comprising a pharmaceutical tablet of one or more layers, one of which carries a biologically active substance; the formulation of said tablet includes different percentages of hydrophilic and lipophilic polymeric materials, and adjuvant substances. The tablets of the present invention show a release rate which is independent from the amounts of active substance present in the tablet.

  • Process for the preparation of crystalline perindopril

    The present invention relates to a new process for the preparation of crystalline perindopril. The present invention also relates to new alkyl ammonium salts of perindopril and the processes for the preparation thereof.

  • Pharmaceutical formulations

    Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.

  • Multifunctional degradable nanoparticles with control over size and functionalities

    In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymer and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  • Stable pharmaceutical products

    Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide.

  • PARTICLE FORMULATIONS FOR USE IN PHARMACEUTICAL COMPOSITIONS

    A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

  • POLYSACCHARIDE COMPOSITION AND METHODS OF ISOLATION OF THE EMULSION STABILIZING CATIONIC POLYELECTROLYTIC POLYSACCHARIDE

    The present invention relates to purification and use of a novel emulsion stabilizing polysaccharide. In particular, a polyelectrolyte exopolysaccharide with high molecular weight comprising a high molecular weight polymer with a tri-saccharide repeating unit is disclosed. In one aspect of the invention, methods are directed to isolating and purifying a high molecular weight exopolysaccharide (EPS) from a cell supernatant. In another aspect, methods are disclosed for isolating a lipopolysaccharide (LPS) and a high molecular weight Acinetobacter polyelectrolyte exopolysaccharide (APE) from Acinetobacter bacteria. Compositions are also directed to lipid nanoparticles comprising a therapeutic agent encapsulated by a high molecular weight polysaccharide and nanoparticles comprising a therapeutic agent bound to a cationic polysaccharide cross-linked with a polyanion.

  • COMPOSITION AND DOSAGE FORM COMPRISING A PARTICLE FORMULATION AND SUSPENDING VEHICLE

    A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

  • TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS

    A delivery vehicle for topical pharmaceutical formulations that include a C2 to C4 alkanol, a polyalcohol, and a monoalkyl ether of diethylene glycol present in relative amounts sufficient to provide permeation enhancement of an active agent through mammalian dermal or mucosal surfaces. Preferably, the delivery vehicle as well as the formulations that contain it are substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters in order to avoid potential undesirable odor and irritation effects caused by such compounds during use of the formulation. Without these additives, use of the formulations is facilitated and patient compliance is greater.

  • Pharmaceutical dosage form for immediate release of an indolinone derivative

    The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate.

  • NOVEL VEGF-2 RECEPTOR AND PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF

    The invention relates to compounds of general formula (I) wherein W, D, E, G, J, L, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and Y are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use--alone or in combination with one or more other pharmaceutically active compounds--in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer and skin and eye diseases. ##STR00001##

  • Pharmaceutical combination

    The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

  • PHARMACEUTICAL COMPOSITIONS OF [5(S)-(2'-HYDROXYETHOXY)-20(S)-CAMPTOTHECIN

    There is provided a powder composition for use in a pharmaceutical product, the composition including a) 5(S)-(2'-hydroxyethoxy)-20(S)-CPT; at least one cyclodextrin; wherein 5(S)-(2'-hydroxyethoxy)-20(S)-CPT includes less than 5% of 5(R)-(2'-hydroxyethoxy)-20(S)-CPT. Preferably, in the powder composition, 5(S)-(2'-hydroxyethoxy)-20(S)-CPT is substantially free from said 5(R)-(2'-hydroxyethoxy)-20(S)-CPT.

  • SURFACE ACTIVE PROTEINS AS EXCIPIENTS IN SOLID PHARMACEUTICAL FORMULATIONS

    The invention relates to a use of surface active hydrophobins for applications in pharmaceutical technology, in particular as excipients for galenic use. Provided is a method for either admixture of hydrophobins to galenic compositions or for treating the surface of pharmaceutical forms with a hydrophobin-containing solution to modify the pharmaceutical properties of the galenic form. In a preferred embodiment of the invention hydrophobins are used to improve the properties of a pharmaceutical composition, e.g. to act as a surfactant or to increase resistance to disintegration of the galenic forms to achieve a retarded drug release. The galenic form to be modified by the use of surface active proteins as excipients can be capsules, tablets, pills, microparticles, vesicles, and suppositories, although further galenic forms are envisioned. The surface active proteins used for the purpose of present invention can either be isolated from their respective natural source or prepared by recombinant techniques and expression in a suitable host.

  • Controlled releasing composition

    A controlled releasing composition comprising a plurality of microparticles and a matrix as well as the preparation method thereof is disclosed. The plurality of microparticles comprise a first material and the matrix comprises a second material. The melting temperature of the first material is higher than the melting temperature of the second material.

  • PHARMACEUTICAL COMPOSITION OF COMPLEX CARBOHYDRATES AND ESSENTIAL OILS AND METHODS OF USING THE SAME

    The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates with or without natural or synthetic essential oils can work effectively as a topical, oral or mucosal pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers and prevent and treat numerous other conditions and diseases. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion, metastatic and coronary cascades.

  • XYLITOL ESTERS AND ETHERS APPLIED AS ALTERNATIVE EMULSIFIERS, SOLVENTS, CO-EMULSIFIERS AND PRESERVATIVE SYSTEMS FOR PHARMACEUTICAL AND COSMETIC PRODUCTS

    This patent application has as purpose the application/utilization of esters and ethers derived from xylitol, obtained by organic synthesis, as alternative emollient, moisturizing, emulsifier and co-emulsifier and preservatives for pharmaceutical, cosmetic and veterinarian products. The molecules required in this invention patent are mainly xylitol esters and ethers associated to the chains of fatty acids and alcohols (FIGS. 1 and 2), applied isolated or in association with other molecules of known preserving and/or moisturizing/emollient actions, such as phenoxyethanol, butylene glycol, glycerin, caprylyl glycol, ethyl hexyl glycerin, phenetyl alcohol, nisin, lactoferrin, among others, as well as in association with other emollient/moisturizing and preservatives for application in cosmetic, pharmaceutical and veterinarian formulations. Some of these associations and isolated applications present important antimicrobial action, such as for example, inhibiting the growth of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Aspergilus niger and Candida albicans. Also, the present co-emulsifier, emollient, solving and moisturizing properties.

  • NANOPARTICLE PHARMACEUTICAL FORMULATIONS

    The present invention is directed to methods of preparing nanoparticles of aqueous-insoluble compounds, particularly aqueous-insoluble bioactive (drug) compounds, and to compositions and medicaments obtained by these methods. These methods, compositions, and other inventive aspects of the present invention are based particularly on the use of bile acid compound(s) to prepare nanoparticles of aqueous-insoluble compounds.

  • Local Anesthetic Emulsion Compositions and Methods of Making and Using the Same

    Local anesthetic emulsion compositions are provided. The local anesthetic emulsion compositions may include: an oily phase comprising a eutectic mixture of a local anesthetic and an acyclic amide; a surfactant; and an aqueous phase. Also provided are methods of making and using the emulsions.

  • KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS

    Described herein are compounds that are inhibitors of one or more protein kinases. Also described are pharmaceutical compositions and medicaments that include the compounds described herein. Also described herein are methods of using such protein kinase inhibitors, alone and in combination with other compounds, for conditions or diseases mediated or dependent upon protein kinases.

  • DRUG ELUTING COMPOSITE

    The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

  • PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES

    Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared.

  • PROCESS FOR PREPARING CARRIER PARTICLES FOR DRY POWDERS FOR INHALATION

    Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.

  • PHASE TRANSITIONING HYDROGELS

    A method of forming and the resulting hydrogel composition comprising poly(vinyl alcohol) at a final concentration of about 20% (w/w) to about 65% (w/w) and polyethylene glycol at a final concentration of about 2% (w/w) to about 20% (w/w), wherein the hydrogel composition has a total polymer content, above about 30% (w/w), higher than the total polymer content of a precursor polymer solution formulated prior to the formulation of the hydrogel composition. The hydrogel composition may further comprise poly(vinyl pyrrolidone) at a fmal concentration of about 0.10% (w/w) to about 0.75% (w/w).

  • Blunt Needle Safety Drug Delivery System

    Drug delivery devices having non-luer connections and adapters and adaption connectors for providing non-luer connections to drug delivery devices are provided. An exemplary drug delivery device for use with a catheter connection includes a blunt needle component with a non-luer connection and a filter component with a non-luer connection, wherein the non-luer connections of the blunt needle component and filter component are incompatible with standard luer fitting and intravenous route-accessing devices. In one or more embodiments, an adapter having a non-luer connection at one end and a luer connector is provided for use with blunt needle components and filter components wherein one of the blunt needle component and the filter component includes a luer connection and the other of the blunt needle component and the filter component includes a non-luer connection. Methods of delivering liquid medication to a catheter are also provided.

  • COATED DRUG DELIVERY FORMULATIONS

    The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.

  • Biodegradable Proline-Based Polymers

    The invention provides sequential poly(ester amide)s derived from Proline and that are synthesized by a two-step method, involving a final thermal polyesterification reaction. Molecular weights of polymers prepared by this method are from 14,000 Da to about 77,000 Da.1 When invention proline-based PEAs were thermally characterized, their glass transition temperatures were lower than other alpha-amino acid based poly(ester amides) due to lack of internal hydrogen bonding. These Proline-based PEAs assemble as nano-particles in aqueous solutions and form complexes with various cations and biologies, including hydrophobic small molecule drugs and biologies. Therefore the invention Proline-based PEAs are useful for drug delivery applications requiring a polymer with a molecular weight in the range from 14,000 Da to about 77,000 Da and for fabrication of nanoparticles for delivery of hydrophobic drugs.

  • PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES

    The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.

  • Pen needle assembly having biodegradable components

    A pen needle assembly (701) includes a hub (731) and a metal needle (721) fixedly connected to the hub (731). A cover member (711) removably receives the hub for covering a first end of the needle (721). A sealing member (741) covers a second end of the needle (721). At least one component of the pen needle assembly (701) other than the metal needle (721) is manufactured of a biodegradable polymer, thereby providing a more environmentally friendly pen needle assembly (701) for a drug delivery device (100).

  • DRUG DELIVERY DEVICE AND METHOD

    A drug delivery device (10) includes a pressurized reservoir (14) in communication with a flow path to an outlet (12). The flow path includes two normally-closed valves (16, 18) and a flow restriction (18). A pressure measurement arrangement (22) measures a differential fluid pressure between two points (24, 26) along the flow path which span at least part of the flow restriction (18), one of the points being between the valves (16, 18). A controller (28) selectively opens the valves (16, 18) to deliver a defined quantity of the liquid medicament to the outlet (12).

  • POLYMER-BASED, SUSTAINED RELEASE DRUG DELIVERY SYSTEM

    Disclosed is a sustained release system that includes a polymer and a prodrug having a solubility less than about 1 mg/ml dispersed in the polymer. Advantageously, the polymer is permeable to the prodrug and may be non-release rate limiting with respect to the rate of release of the prodrug from the polymer. This permits improved drug delivery within a body in the vicinity of a surgery via sustained release rate kinetics over a prolonged period of time, while not requiring complicated manufacturing processes.

  • PHARMACEUTICAL COMPOSITION CONTAINING A DRUG AND SIRNA

    The present invention relates generally to the fields of molecular biology, medicine, oncology, and delivery of therapeutic compounds. In particular, the present invention relates to pharmaceutical compositions containing a hydrophobic drug substance and an inhibitory nucleic acid molecule, such as short interfering RNA (siRNA), in a single drug delivery system, as well as a process for making and a process for administering the same.

  • CLOSTRIDIUM TAENIOSPORUM SPORES AND SPORE APPENDAGES AS SURFACE DISPLAY HOSTS, DRUG DELIVERY DEVICES, AND NANOBIOTECHNOLOGICAL STRUCTURES

    The present disclosure relates to spore surface display compositions comprising a spore having at least one nucleic acid sequence encoding for at least one polypeptide and operable to express the polypeptide on a surface of the spore. In some embodiments, the displayed polypeptide is displayed with a spore carrier protein. In some embodiments, the spore may be derived from a Clostriduim sp. such as Clostriduim taeniosporum. Spore display compositions of the disclosure may include vaccines, fusion proteins, drug delivery devices, systems for generating an antibody to an antigen/peptide expressed on a spore surface, an anticancer drug, an immobilized enzyme system, a system for serological reagent preparation, a contaminant removal system, a biocatalysis system, a screening platform, a nanotechnology platform, a bioanalytical sensor, a molecular electronic system and/or a signal processing system. Methods for making and using these compositions are described.

  • Pharmaceutical composition of nanoparticles for protein drug delivery

    The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

  • SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION

    A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.

  • TABLET FORMULATION FOR P38 INHIBITOR AND METHOD

    A tablet formulation is provided which includes a medicament which is a pharmaceutically acceptable salt of a p38 inhibitor, such as the p38 HCl salt of the structure Formula (I) and which has good physical stability when stored at up to 25 C./60% RH in closed containers with desiccant. The tablet formulation will contain crospovidone as a tablet disintegrant, which, unlike croscarmellose sodium, will not cause disproportionation of the HCl salt to the free base of P38 inhibitor and thus will have acceptable dissolution properties even after storage at room temperature. ##STR00001##

  • NITRIC OXIDE GENERATOR AND NON-DELIQUESCENT TABLET FOR USE IN SAME

    An apparatus to generate nitric oxide is disclosed in one embodiment in accordance with the invention as including a heat source and a vessel containing the heat source. A tablet may be placed within the vessel such that it is in thermal communication with the heat source to receive heat therefrom. The tablet may contain reactants that are substantially non-deliquescent and form nitric oxide in response to heat from the heat source.

  • PROCESS OF MANUFACTURING A STABLE SOFTGEL CAPSULE CONTAINING MICROENCAPSULATED PROBIOTIC BACTERIA

    A softgel capsule containing microencapsulated probiotic bacteria is manufactured such that the softgel capsule is stable for at least about 24 months at room temperature.

  • Chewable Soft Capsule

    A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided.

  • Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl) Phenol

    A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.

  • PUMP SYSTEMS AND METHODS FOR STORING AND DISPENSING A PLURALITY OF PRECISELY MEASURED UNIT-DOSES OF IMIQUIMOD CREAM

    The present invention is directed to airless storage and dispensing systems that include a pump or dispensing package pre-filled with a topical semi-solid imiquimod pharmaceutical formulation ("pump systems") and methods for storing and dispensing from the pump systems a plurality of precisely measured and uniform unit doses of a topical semi-solid imiquimod pharmaceutical formulation, and more particularly to pump systems, pre-filled with a topical imiquimod pharmaceutical cream and methods for delivering multiple precisely measured unit doses of a topical imiquimod pharmaceutical cream, and methods for using a controlled delivery pump system to store and dispense a plurality of consistent and precisely measured unit doses of a topical imiquimod pharmaceutical cream for use in topically treating a dermal and mucosal-associated condition, such as, external genital warts and/or perianal warts (EGWs), actinic keratosis or actinic keratoses (AK or AKs) and superficial basal cell carcinoma (sBCC).

  • METHOD AND APPARATUS FOR SEALING MEDICINAL CAPSULES

    A method of sealing parts of a plastic capsule by forming a weld seam in an overlapping region of the parts of the capsule, wherein the capsule comprises a capsule cap having an open end and a capsule body having an open end, and capsules formed by such method. The capsules produced by the process according to the invention are disposable and preferably contain a single dose of a pharmaceutical formulation in the form of a powder or liquid intended to be administered by inhalation and are suitable by their form and function for use in powder inhalers or liquid nebulizers for producing aerosols. Aerosols thus produced can be inhaled, for example, in order to administer a pharmaceutical formulation to the lungs.

  • ORAL CONTROLLED RELEASE DOSAGE FORMS FOR WATER SOLUBLE DRUGS

    Disclosed herein is an oral controlled release pharmaceutical formulation comprising water-soluble drug or pharmaceutically acceptable salts thereof, in a hydrophilic matrix system, further comprising pH independent polymers present in an amount of 5% to 90% w/w in combination with acid insoluble polymer present in an amount of 1% to 70% w/w and/or a diluent, a lubricant and/or a glidant.

  • LIQUID PHARMACEUTICAL FORMULATION CONTAINING PARACETAMOL

    The present invention relates to a sugar-free liquid pharmaceutical formulation comprising an aqueous solution of paracetamol, a solubilizing agent containing polyethylene glycol, a thickening agent containing xanthan gum, and a sweetening system containing sucralose and a mixture of polyols containing glycerol, sorbitol and xylitol in a total amount between approx. 15% and 35% w/v relative to the total volume of said pharmaceutical formulation.

  • PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT

    Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

  • METHOD FOR PREPARING A PHARMACEUTICAL FORMULATION OF LANTHANIDE CHELATE IN POWDER FORM

    The present invention relates to a method for preparing a pharmaceutical formulation of lanthanide chelate in powder form, this powder comprising a mol/mol excess of free chelate of between 0.002 and 0.4%, said method comprising the following successive steps: 1) step 1: mixing the chelate and the lanthanide so as to obtain complexation of the lanthanide by the chelate, the complexation solution obtained comprising, in addition to the chelate-lanthanide complex, an excess amount X1 of free chelate; 2) step 2: preferably measuring X1; 3) step 3: precipitating the complexation solution obtained in step 1) from an organic solvent so as to obtain a powder of chelate-lanthanide complex, the powder containing an excess amount X2 of free chelate; 4) step 4: optionally adjusting X2 so as to obtain: 4.a) X2 is between 0.002 and 0.4%, and more especially between 0.02 and 0.3% mol/mol, very advantageously between 0.025 and 0.25% mol/mol, 4.b) X2 corresponds to between 0.2 and 2 times X1, in particular between 0.5 and 1.5 times X1, X2 advantageously belonging to the range: [0.5-0.95].times.X1, or to the range [1.05-1.3].times.X1; 5) step 5: preferably measuring X2.

  • INHIBITION OF PRION PROTEIN PROPAGATION BY RECEPTOR ASSOCIATED PROTEIN (RAP), ITS DERIVATIVES, MIMETICS AND SYNTHETIC PEPTIDES

    A pharmaceutical formulation and method of treatment of prion disease include a RAP agent with a pharmaceutically acceptable carrier and/or excipient, and the administration of same to a subject suffering from or at risk of a prion disease. The RAP agent is an effective means for the prevention and/or treatment of various prion diseases regardless whether the disease is acquired by infection or by genetic mutation.

  • Pharmaceutical Formulations Containing Corticosteroids for Topical Administration

    The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.

  • ATTENUATED FNR DEFICIENT ENTEROBACTERIA

    The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention.

  • LONG-ACTING FORMULATIONS OF INSULINS

    The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

  • INJECTABLE MECLIZINE FORMULATIONS AND METHODS

    Methods of treating or preventing a vertigo, nausea, or vomiting condition comprising injecting a subject with a pharmaceutically acceptable formulation consisting essentially of an effective amount of meclizine or a pharmaceutically acceptable salt thereof, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and about 7 are disclosed. An injectable pharmaceutical formulation for treating or preventing a vertigo, nausea, or vomiting condition consisting essentially of an effective amount of meclizine, a chemically modified cyclodextrin, and an aqueous carrier medium having a pH between about 2 and about 7 is also disclosed.

  • PHARMACEUTICAL FORMULATIONS AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS

    The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca.sup.+2 to Na.sup.+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.

  • Novel Method For Treating Breathing Disorders or Diseases

    The present invention includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising (+)-doxapram or a salt thereof, and a pharmaceutically acceptable carrier, wherein the formulation is essentially free of (-)-doxapram or a salt thereof.

  • Compositions and Methods for Treating Type II Diabetes and Related Disorders

    The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl). The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention.

  • COMPOSITIONS FOR INTRANASAL DELIVERY OF HUMAN INSULIN AND USES THEREOF

    What is described is a pharmaceutical formulation for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, a surface active agent, and a thickening agent, wherein said formulation provides a ultra-rapid acting profile to regular human insulin.

  • LAYERED PHARMACEUTICAL FORMULATIONS

    In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.

  • FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF

    The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

  • Regulatory T Cells and Their Use in Immunotherapy and Suppression of Autoimmune Responses

    Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4.sup.+CD25.sup.+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use

  • Pharmaceutical Dosage Forms for the Release of Active Compounds

    Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.

  • LIQUID PROPELLANT-FREE FORMULATION COMPRISING AN ANTIMUSCARINIC DRUG

    Liquid, propellant-free pharmaceutical formulation for administration by nebulization which comprising an antimuscarinic drug as active ingredient are useful for the prevention and/or treatment of a wide range of conditions including respiratory disorders.

  • LIQUID PROPELLANT-FREE FORMULATION COMPRISING AN ANTIMUSCARINIC DRUG

    Liquid, propellant-free pharmaceutical formulation for administration by nebulization which comprising an antimuscarinic drug as active ingredient are useful for the prevention and/or treatment of a wide range of conditions including respiratory disorders.

  • MODIFIED RELEASE FORMULATION OF LACOSAMIDE

    The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal C.sub.max to C.sub.min peak to trough variation over a period of at least 12 hrs.

  • INJECTABLE FORMULATION FOR TREATMENT AND PROTECTION OF PATIENTS HAVING AN INFLAMMATORY REACTION OR AN ISCHEMIA-REPERFUSION EVENT

    Compounds according to formula (I) are particularly suitable for the treatment and/or prevention of a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue. Furthermore, the invention relates to the use of said compounds for preparing a medicament and to pharmaceutical preparations comprising such compounds. The invention also relates to methods of treating or protecting patients having or being prone to develop a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue, the methods comprising administration of a therapeutically effective amount of such compounds

  • Methods Of Loading A Hollow Stent With A Drug Or Drug Formulation

    A method of loading a composition into a structural element of a stent, where the structural element is defined by a lumen and at least one opening to access the lumen. The composition may comprise a therapeutic agent, and wherein at a temperature of 30.degree. C. and at one atmosphere, the composition may be in a solid state or semi-solid state.

  • Methods Of Drug Loading A Hollow Stent With A High Viscosity Formulation

    A method of loading a composition into a structural element of a stent, where the structural element is defined by a lumen and at least one opening to access the lumen. The composition may include a therapeutic agent. In some embodiments, the composition has characteristics such that at a temperature of 20.degree. C. to 30.degree. C. and a pressure of one atmosphere, the viscosity of the composition is about 10 cP or greater than 10 cP.

  • FORMULATION FOR LIPOPHILIC AGENTS

    The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same

  • Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration

    Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr ("linaclotide") or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

  • ANTIBIOTIC PRODUCT, USE AND FORMULATION THEREOF

    An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the C.sub.max for the antibiotic product being reached in less than about twelve hours after the initial release of antibiotic. In one embodiment, there is a delayed release dosage form, as well as two or more delayed sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a C.sub.max at different times.

  • Liposomal formulation and use thereof

    Cationic liposome encapsulated antimonial drugs formulations are provided. The drug-loaded liposome have enhanced efficacy as antileismanial agents and provide improved therapeutic index as compared to the minimal dose of free drug.

  • Pharmaceutical Formulation

    The invention relates to a pharmaceutical formulation including, as an active principle, the compound of formula (I) ##STR00001## or a salt of said compound with a pharmaceutically acceptable acid

  • Pellets Formulation

    A process for preparing pellets by high shear granulation containing a pharmaceutical active ingredient with a pH dependent water solubility, the pellets obtained with said process and pharmaceutical oral dosage forms comprising said pellets

  • STABLE LOW DIGESTIVE ENZYME CONTENT FORMULATION

    The present invention is directed to a pharmaceutical composition or dosage form having a stable, low (diluted) digestive enzyme content comprising at least one digestive enzyme and at least one carrier, or a dosage form thereof. The invention is also directed to a process of preparation of the composition or the dosage form. In addition the invention is directed to the treatment and prevention of disorders or conditions associated with a digestive enzyme deficiency in a patient in need thereof, comprising administering to said patient a pharmaceutically acceptable amount of the composition having a stable low digestive enzyme content or dosage form thereof.

  • PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND IRRITANT AGENT

    Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering

  • TOPICAL FORMULATION FOR DIABETIC FOOT ULCERS

    This invention relates to a new topical gel formulation of the drug Esmolol hydrochloride for treatment of chronic wounds such as diabetic wounds, burn wounds, venous ulcers and pressure ulcers.

  • Intravenous Formulation with Water-Soluble CoCrystals of Acetylsalicylic Acid and Theanine

    An aspirin-theanine cocrystal composition including a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer combined with the quantity of acetylsalicylic acid in a mixture. The theanine enantiomer may be L-theanine, D-theanine, or DL-theanine

  • LIPID FORMULATION

    The invention features a cationic lipid of formula I, ##STR00001## an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

  • Methods Of Loading A Hollow Stent With A Drug Or Drug Formulation

    A method of loading a composition into a structural element of a stent, where the structural element is defined by a lumen and at least one opening to access the lumen. The composition may comprise a therapeutic agent, and wherein at a temperature of 30.degree. C. and at one atmosphere, the composition may be in a solid state or semi-solid state.

  • EXTENDED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF

    Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.

  • PHARMACEUTICAL FORMULATION FOR PROTEINS

    The present invention provides a liquid pharmaceutical formulation comprising a therapeutic protein, a surfactant and at least an antioxidant selected from the group of radical scavengers, chelating agents or chain terminators.

  • POLYMER GEL FORMULATION

    A polymer gel, in at least some embodiments, featuring both cross-linked castor oil and branched castor oil components, in which the castor oil is optionally replaced by ricinoleic acid.

  • USE OF INHALABLE POWDER FORMULATION COMPRISING GROWTH HORMONE FOR PREVENTING OR TREATING NMDA RECEPTOR HYPOFUNCTION-RELATED DISEASES

    A use of an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease, a method for preventing or treating an NMDA receptor hypofunction-related disease in a subject, which comprises administering a therapeutically effective amount of an inhalable powder formulation comprising growth hormone (GH) to the subject in need thereof, and an inhalable powder formulation for preventing or treating an NMDA receptor hypofunction-related disease comprising GH as an active ingredient are provided.

  • DELAYED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF

    Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.

  • NOVEL PARENTERAL CARBAMAZEPINE FORMULATION

    The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.

  • FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS

    A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.

  • FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY

    Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-.alpha.4.beta.7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-.alpha.4.beta.7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-.alpha.4.beta.7 antibody in vivo.

  • POLYMER NANOPARTICLE INJECTION FORMULATION COMPOSITION CONTAINING RAPAMYCIN WITH IMPROVED WATER SOLUBILITY, PREPARATION METHOD THEREOF, AND ANTICANCER COMPOSITION FOR COMBINED USE WITH RADIOTHERAPY

    The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy.

  • STABILIZED FORMULATION FOR ORAL ADMINISTRATION OF THERAPEUTIC AGENTS AND RELATED METHODS

    Stable formulations for the oral administration of therapeutic agents, methods for administering therapeutic agents using the formulations, and methods for treating conditions and diseases using the formulations.

  • FORMULATION FOR HGH AND RHIGF-1 COMBINATION

    The present invention relates to pharmaceutical compositions. More particularly, the invention relates to formulations of growth hormone (GH) and insulin-like growth factor (IGF-1) combination compositions which provide stable pharmaceutical compositions without aggregation formation at a desirable pH, and to processes of preparation thereof.

  • Transdermal Patch Formulation

    A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to provide a composition, applying the composition obtained in step (a) to a carrier material to form a substrate layer of the transdermal patch, wherein the retaining means remain within the final transdermal patch.

  • SOLUBILIZED FORMULATION OF DOCETAXEL WITHOUT TWEEN 80

    Lyophilizates containing docetaxel and the use thereof in preparing concentrated liquid formulations, and ready to use formulations for injection, as well as such concentrates and ready to use formulations themselves are disclosed in which Tween surfactants are avoided so that hypersensitivity reactions to Tween surfactants can be avoided and docetaxel can be administered at higher doses and/or for longer periods of time and/or for additional treatment cycles.

  • DELAYED RELEASE RASAGILINE FORMULATION

    Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.

  • DELAYED RELEASE RASAGILINE FORMULATION

    The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments.

  • PHARMACEUTICAL FORMULATION AND PROCESS COMPRISING A SOLID DISPERSION OF MACROLIDE (TACROLIMUS)

    The present invention relates to a pharmaceutical formulation and process for preparing the same comprising an oral dosage formulation, such as a capsule formulation, of a macrolide compound, such as tacrolimus, wherein the capsule formulation contains both a solid dispersion of the macrolide along with a non-dispersed form of the macrolide. The pharmaceutical formulation according to the invention is bioequivalent to the FDA approved product according to a bioavailability study conducted in humans.

  • DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS

    Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.

  • CONTROLLED RELEASE CARVEDILOL FORMULATION

    A controlled release carvedilol formulation for less frequent, preferably once daily administration is described. The controlled release formulation comprises a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt thereof, a matrix forming polymer, a solubility enhancer and a pharmaceutically acceptable carrier. In one embodiment, a controlled release formulation having a therapeutically effective amount of carvedilol is contained in two or more subunits having different release profiles. The controlled release formulation is usable in the treatment and/or prophylaxis of one or more conditions such as cardiovascular disorders.

  • Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes

    A new topical formulation is provided, with a high chemical stability, of for example a low dose clobetasol propionate, suitable for the topical treatment of skin and mucous membrane conditions associated with disorders including psoriasis, eczema, and other forms of dermatitis and also topical use associated with he mouth, such as lichen planus. The formulation includes an aqueous vehicle of based on propylene glycol as a solvent and moisture-retaining agent, and macrogol-glycerol hydroxystearate as a non-ionic emulsifier, being capable of holding surprisingly low concentrations of clobetasol. The vehicle holds concentrations about 0.005% to about 0.05% by weight of 17-clobetasol propionate, more preferably about 0.02 to 0.025%, even more preferably 0.025% by weight of 17-clobetasol propionate. The formulation has a good chemical stability, resulting in a long durability.

  • PHARMACEUTICAL FORMULATION CONTAINING IMMUNOGLOBULIN

    A set of at least two different protein conjugate preparations, each protein conjugate preparation comprising histidine as a buffering agent and a protein conjugate comprising one or more immunoglobulin moieties conjugated to a carrier protein; wherein the immunoglobulin moieties of each element of said set of protein conjugate preparation have identical complementarity determining regions (CDRs); and wherein different protein conjugate preparations differ in that the immunoglobulin moieties of the protein conjugates have different CDRs.

  • PHARMACEUTICAL FORMULATION FOR USE IN SPINAL FUSION

    A pharmaceutical formulation for use in a spinal fusion method, comprising a composition for forming a matrix, a kit comprising the composition, a pharmaceutical product obtainable from the pharmaceutical formulation, and an interbody spinal fusion cage containing the pharmaceutical formulation or the pharmaceutical product are described herein. The composition comprises at least a first matrix material precursor component and a second matrix material precursor component that are able to crosslink to form the matrix under appropriate conditions, a bioactive factor that is biologically active for stimulating bone formation between two vertebrae and for effecting or supporting spinal fusion. The bioactive factor is PTH, optionally a PTH fusion peptide. The bioactive factor is releasably incorporated in the matrix upon crosslinking of the matrix material precursor components.

  • VACCINE FORMULATION OF MANNOSE COATED PEPTIDE PARTICLES

    A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell.

  • TWO PART FORMULATION SYSTEM FOR OPTHALMIC DELIVERY

    Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.

  • PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTAN

    Provided is a pharmaceutical formulation in the form of a bilayered tablet consisting of a first layer containing irbesartan or a pharmaceutically acceptable salt thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia.

  • Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration

    An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.

  • LONG-ACTING HUMAN FOLLICLE-STIMULATING HORMONE FORMULATION USING IMMUNOGLOBULIN FRAGMENT

    The present invention relates to a long-acting human follicle-stimulating hormone formulation having improved in vivo duration and stability, comprising a human follicle-stimulating hormone conjugate that is prepared by covalently linking human follicle-stimulating hormone with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting human follicle-stimulating hormone formulation of the present invention maintains in vivo activity of human follicle-stimulating hormone at a relatively high level and remarkably increases the serum half-life thereof.

  • ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS

    The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.

  • NOVEL EPOPROSTENOL FORMULATION AND METHOD OF MAKING THEREOF

    This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30.degree. C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed.

  • DRY POWDER FORMULATION CONTAINING TIOTROPIUM FOR INHALATION

    The present invention is related to a dry powder formulation containing tiotropium to be administered via inhalation, the use of said formulation in the treatment of respiratory diseases especially asthma and COPD (Chronic obstructive pulmonary disease), and the production process of said formulation.

  • PHARMACEUTICAL FORMULATION CONTAINING PHENYTOIN SODIUM AND MAGNESIUM STEARATE

    The present invention relates to a novel pharmaceutical formulation comprising phenytoin sodium, a high amount of magnesium stearate, and a low level of a hydrophilic polymer such as a methocel, and a method of preparing the same by blending.

  • STABLE AQUEOUS FORMULATION OF (E)-4-CARBOXYSTYRYL-4-CHLOROBENZYL SULFONE

    An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of a radioprotective .alpha.,.beta.-unsaturated aryl sulfone, a cosolvent comprising polyethylene glycol (PEG), polypropylene glycol, polyglycerol, DMA, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and a water soluble Vitamin E derivative, wherein the composition has a pH within the range of about 7.0 to about 9.5.

  • INJECTABLE DEPOT FORMULATION COMPRISING CRYSTALS OF ILOPERIDONE

    An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.

  • INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE

    A water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.

  • NOVEL FORMULATION AND TREATMENT METHODS

    The invention relates to extended release compositions and formulations comprising 6-thioguanine (6-TG), and methods for treating diseases or conditions responsive to 6-TG.

  • FORMULATION FOR RELIEF OF COLD AND FLU SYMPTOMS

    A nutritional composition or functional food composition is provided comprising homeopathic ingredients for relieving the symptoms of colds and/or flus, in combination with traditional herbal and nutraceutical ingredients, and are efficacious as antipathogens. The formulation includes ingredients balanced in a synergistic manner to elicit complementary effects which both reduce the symptoms of colds and/or flus and provide the potential to reduce pathogenic loads in the body. Methods of making both the core medicinal formulation and suitable dietary supplement and/or functional food embodiments based on the formulation are provided.

  • Solid Pharmaceutical Dosage Formulation

    The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor.

  • ENZYMATIC PERACID GENERATION FORMULATION

    Disclosed herein are multi-component formulations for enzymatically producing aqueous solutions of peroxycarboxylic acids suitable for use in, e.g., disinfectant and/or bleaching applications. The multi-component peroxycarboxylic acid formulations comprise at least one carbohydrate esterase family 7 enzyme having perhydrolytic activity.

  • Injectable dosage form of flupirtine

    The present invention relates to a flupirtine-containing lyophilisate, the use of this lyophilisate to produce a pharmaceutical composition to be parenterally applied, a procedure to produce a flupirtine-containing pharmaceutical composition to be parenterally applied, and a procedure to produce the flupirtine-containing lyophilisate as well as the flupirtine-containing pharmaceutical composition produced using the lyophilisate. For this purpose a lyophilisate is provided which contains the active ingredient flupirtine in the form of a physiologically tolerated salt, which has a solubility in water of at least 2.5 mg/ml, preferably at least 5 mg/ml, especially preferably at least 10 mg/ml, and contains one or more cyclodextrins or cyclodextrin derivatives, and which may be used to produce a pharmaceutical composition to be parenterally applied.

  • METHOD OF PREPARING AN ORAL DOSAGE FORM COMPRISING FINGOLIMOD

    The present invention relates to a method of preparing an intermediate containing fingolimod, a method of prep.

  • Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist

    A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release profile of the opioid agonist essentially corresponds to the in vitro release profile of the opioid antagonist, and wherein the opioid agonist and the opioid antagonist are intimately mixed with one another and homogeneously dispersed in the polyalkylene oxide. The pharmaceutical dosage form is useful, for example, to treat pain in a patient in need of such treatment.

  • Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist

    A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release profile of the opioid agonist essentially corresponds to the in vitro release profile of the opioid antagonist, and wherein the opioid agonist and the opioid antagonist are intimately mixed with one another and homogeneously dispersed in the polyalkylene oxide. The pharmaceutical dosage form is useful, for example, to treat pain in a patient in need of such treatment.

  • Solid Oral Dosage Form Containing An Enhancer

    The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

  • Lingual Vestibular Dosage-form and Delivery System for Transmucosal Administration of Pharmaceutical Agents

    A pharmaceutical delivery system enabling the oral transmucosal administration of active pharmaceutical agents in a situation where rapid transmucosal administration is preferred to prevent the delay and decomposition of the agents in passing through the intestinal tract. The delivery system comprises a supportive substrate with bilateral lingual vestibular flanges connected at the anterior midline to form a `U` like shape for fitting in the potential space of the bilateral lingual vestibules, and further comprising a handle or tab for holding the device in the mouth of a patient with altered consciousness to prevent aspiration or premature swallowing. The pharmaceutical dosage-form is formulated and shaped to contact the mucosal tissues and may include mucoadhesive compounds, retentive compounds, and/or additional payload enhancers, such as permeation enhancers and flavor enhancers.

  • SOLID PHARMACEUTICAL DOSAGE FORM

    A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50.degree. C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.

  • MODIFIED RELEASE DOSAGE FORM COMPRISING DESVENLAFAXINE OR SALTS THEREOF

    The present invention refers to a modified release pharmaceutical composition comprising desvenlafaxine or salts thereof, a release rate modifying system that controls the release of active agent(s) in both acidic and basic environments. A process of making and method of using the above-described composition is also disclosed.

  • Dosage Form for Insertion Into the Mouth

    Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly anti-migraine agents to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.

  • LOW RESIDUAL SOLVENT POLYAMIDEIMIDE POWDER FROM SUSPENSION POLYMERIZATION

    Disclosed is a method for generating a fine slurry of polyamideimide resin which can be conveniently isolated and dried. The product is completely free of dialkylamide solvents or other toxic substances.

  • LOW RESIDUAL SOLVENT POLYAMIDEIMIDE POWDER FROM SUSPENSION POLYMERIZATION

    Disclosed is a method for generating a fine slurry of polyamideimide resin which can be conveniently isolated and dried. The product is completely free of dialkylamide solvents or other toxic substances.

  • HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF

    The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

  • Process for Continuous Emulsion Polymerization

    A process for aqueous, free-radically initiated, continuous emulsion polymerization of A) at least one vinyl ester and optionally at least one (meth)acrylic ester, B) ethylene, and C) 0 to 10% by weight of one or more ethylenically unsaturated, functionalized comonomers, in the presence of 3.0 to 12.5% by weight of one or more emulsifiers, where at least 50% by weight are nonionic emulsifiers, and 0 to 10% by weight of one or more protective colloids, in a stirred tank cascade with at least two pressure reactors connected in series and with at least one low-pressure reactor connected downstream.

  • OIL-IN-WATER EMULSION COMPOSITION AND METHOD FOR PRODUCING SAME

    There is provided an oil-in-water emulsion composition whose continuous phase is an aqueous phase, but which has a high moisture evaporation suppressing effect and is also superior in feeling, and a method for producing the same. An oil-in-water emulsion composition containing an oily component having an inorganic value of 2500 or less, an organic value of 5000 or less and an IOB value of 0.3 to 0.5, the oil-in-water emulsion composition containing the following components (A) to (C) in an aqueous phase. (A) a polyoxyethylene alkyl or alkenyl ether having alkyl group or alkenyl group having 20 to 24 carbon atoms and an average molar number of ethylene oxide added of 1.5 to 4 (B) a polyhydric alcohol (C) a water-soluble polymer

  • Novel Organopolysiloxane, Surfactant, Emulsion Composition, Powder Treatment Agent, Thickening Agent Of Oil-Based Raw Material, Gelling Agent, Gel Composition, And Cosmetic Raw Material Comprising Novel Organopolysiloxane, As Well As, Preparation For External Use And Cosmetic Comprising The Same

    The present invention provides a novel organopolysiloxane in which a rich hydrophilic property is exhibited, not only superior miscibility with a hydrophilic component and but also a hydrophobic property are exhibited, and superior miscibility with both a silicone oil and a non-silicone oil such as a hydrocarbon oil, an ester oil or the like, and provide various usages of the aforementioned novel organopolysiloxane by developing the superior characteristics thereof such as good surface activity power, a distinctive sensation during use, increased stability and the like. A co-modified organopolysiloxane having a specified chemical structure in which a sugar alcohol-modified group and a long-chain hydrocarbon group are present in one molecule is produced. The co-modified organopolysiloxane is blended, as a surfactant, a powder treatment agent, a gelling agent or the like, or as a cosmetic raw material appropriately together with powder(s), oil agent(s) or the like, in a preparation for external use, and in particular, a cosmetic.

  • OIL-IN-WATER TYPE EMULSION SKIN COSMETIC

    An oil-in-water type emulsion skin cosmetic which can be spread on skin easily. The formulation can contain glycerin at a high concentration or a formulation containing a combination of glycerin and an acrylamide-type thickening agent without the sticky effect. The skin cosmetic is characterized by comprising (A) a D-amino acid or a derivative or salt thereof, (B) a homopolymer, a copolymer or a crosspolymer containing at least one component selected from 2-acrylamide-2-methylpropanesulfonic acid, acrylic acid and derivatives thereof as a constituent unit, (C) an ester oil with an IOB value of 0.2 to 0.6, and (D) glycerin.

  • ONE STEP METHOD FOR THE PREPARATION OF WATER/OIL/WATER TYPE MULTIPLE EMULSION

    The present invention relates to a process for preparing a multiple emulsion, particularly a water-in-oil-in-water emulsion in a single step using a single non ionic hydrophilic emulsifier that stabilizes the multiple emulsion for a period of one month. Further, the process uses low levels of a single emulsifier that makes the multiple emulsion find its application in any cosmetic, pharmaceutical and food industry catering to the specificity of the quantity of the emulsifier permissible within a particular industry and also acknowledging the quality of the final product required to be obtained for subsequent application and use thereof.

  • DELAYED-RELEASE FORMULATION FOR REDUCING THE FREQUENCY OF URINATION AND METHOD OF USE THEREOF

    Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.

  • NOVEL FORMULATION OF DICLOFENAC

    The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.

  • FORMULATION SUITABLE FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENTS

    A formulation free of protein which stabilizes pharmaceutical active proteins, peptides, or mixtures thereof in large scale production processes comprising a mixture of a hydrophilic polymer and a non-ionic detergent, and a mixture of a polyalcohol and a sugar. In some embodiments the polyalcohol is absent.

  • Pharmaceutical Formulation Containing Gelling Agent

    Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

  • ORAL PHARMACEUTICAL FILM FORMULATION FOR BITTER TASTING DRUGS

    The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agent(s).

  • STABLE READY TO USE INJECTABLE PARACETAMOL FORMULATION

    The invention concerns a stable aqueous paracetamol solution for use in IV infusion comprising at least one stabilizing-dissolving compound for paracetamol in solution selected from the group consisting of cyclodextrins, at least one stabilizing compound bearing at least one thiol functional group and at least one stabilizing compound selected from the group consisting of Thiamine salts.

  • FORMULATION FOR THE PREVENTION OF CARDIOVASCULAR DISEASE

    This invention relates to a method for the prevention of cardiovascular disease, a formulation for the prevention of cardiovascular disease, the use of specified active principals for the manufacture of such a formulation for use in the method and to a method of preparing said formulation. The formulation of the present invention is a combination of active principals for use in the prevention of cardiovascular disease, notably ischaemic heart disease (including heart attacks) and stroke among the general adult population.

  • POLYSACCHARIDE GEL FORMULATION HAVING INCREASED LONGEVITY

    Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. In some embodiments, the incorporating step comprises 1) mixing the at least one inhibitor with the at least one polysaccharide at a highly hydrated state thereby encapsulating the at least one inhibitor in a polysaccharide network, and 2) dehydrating the polysaccharide network thereby controlling release kinetics or final swell ratio. In another embodiment, the incorporating step comprises 1) encapsulating at least one inhibitor into a biocompatible or biodegradable vessel and 2) combining the polysaccharide and the vessel into a gel formulation. The polysaccharide gel formulations described herein can be used for a variety of cosmetic applications.

  • CHOLESTEROL LOWERING AGENT, NEUTRAL FAT LOWERING AGENT, BLOOD GLUCOSE LEVEL LOWERING AGENT, CHOLESTEROL ADSORBENT, ADSORBENT, NEUTRAL FAT ADSORBENT, HEALTHY FOOD, HEALTH SUPPLEMENT, FOOD WITH NUTRIENT FUNCTION CLAIMS, FOOD FOR SPECIFIED HEALTH USE, QUASI-DRUG, AND PHARMACEUTICAL DRUG

    [Object] To provide a cholesterol lowering agent, a neutral fat lowering agent, a blood glucose level lowering agent, a cholesterol adsorbent, and a neutral fat adsorbent, which have high safety. [Solving Means] A cholesterol lowering agent, a neutral fat lowering agent, a blood glucose level lowering agent, a cholesterol adsorbent, and a neutral fat adsorbent include a porous carbon material having a specific surface area value of 10 m.sup.2/g or more and a pore volume of 0.1 cm.sup.3/g or more, the specific surface area value being measured by a nitrogen BET method, the pore volume being measured by a BJH method and an MP method.

  • Wayside Measurement of Railcar Wheel to Rail Geometry

    Considerable damage to rails, wheels, and trucks can result from geometric anomalies in the wheelsets, rails, and truck hardware. A solution for identifying and quantifying geometric anomalies known to influence the service life of the rolling stock or the ride comfort for the case of passenger service is described. The solution comprises an optical system, which can be configured to accurately perform measurements at mainline speeds (e.g., greater than 100 mph). The optical system includes laser line projectors and imaging cameras and can utilize structured light triangulation.

  • METHOD FOR MANAGING ENVIRONMENTAL, HEALTH AND SAFETY RISKS IN A MANUFACTURING ENVIRONMENT

    A method is provided for managing environmental, health and safety (EHS) risks in a manufacturing environment. Risk assessment data received from a first risk assessment database and a second risk assessment database is stored in an EHS risk assessment database. The risk assessment data includes a plurality of first risk assessments and a plurality of second risk assessments for the manufacturing environment. The first risk assessments may be indicative of ergonomic risk assessments, machine guarding risk assessments, industrial hygiene risk assessments, incident investigation risk assessments, or lock-out tag-out risk assessments. The first risk assessments and the second risk assessments are processed to prioritize the risk assessments, and a notification is provided indicative of the prioritized risk assessments.

  • Amphoteric Liposome Formulation

    The invention relates to compositions and methods to inhibit gene expression. In particular, the invention provides DNAi oligonucleotides sequestered by amphoteric liposomes for the treatment of cancer.

  • PHARMACEUTICAL FORMULATION FOR BEDWETTING AND METHOD OF USE THEREOF

    Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

  • STORAGE-STABLE FORMULATION OF PARACETAMOL IN AQUEOUS SOLUTION

    The present invention relates to a method for the production of a formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent, comprising the steps of (i) dissolving paracetamol in an aqueous solvent comprising an isotonic agent that is sodium chloride and a buffer agent that is sodium citrate, having a temperature between 65.degree. C. and 95.degree. C. and having pH between 5.0 and 6.0 in a reaction vessel, (ii) replacing the remaining air in the vessel by an inert gas, such as nitrogen, and cooling the solution so formed to a temperature below 38.degree. C., (iii) adding cysteine hydrochloride to the solution without mechanical agitation, and (iv) closing the reaction vessel and mechanically agitating the solution in a nitrogen atmosphere. The further relates to a formulation prepared according to the method.

  • PHARMACEUTICAL FORMULATION CONTAINING OPIOID AGONIST, OPIOID ANTAGONIST AND GELLING AGENT

    Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.

  • PHARMACEUTICAL FORMULATION FOR TOPICAL ADMINISTRATION COMPRISING B220

    A pharmaceutical composition for topical administration including 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier. The composition is useful for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject.

  • PELLET FORMULATION FOR THE TREATMENT OF THE INTESTINAL TRACT

    An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.

  • CURCUMINOID SOLID DISPERSION FORMULATION

    A curcuminoid formulation, comprising a melt-processed solid dispersion product comprising one or more curcuminoids, a nutritionally acceptable thermoplastic polymer, and a phosphatide; providing an improved oral bioavailability compared to non-formulated crystalline curcuminoid. A method for producing said formulation. A nutritional product fortified with said formulation. Said formulation for use in the treatment or prophylaxis of cancer, conditions involving an inflammatory reaction, neurological disorders, cardiovascular disease, pulmonary disease, the formation of cholesterol gallstones, and parasitic infestation.

  • SOLUBILIZED CAPSULE FORMULATION OF 1,1-DIMETHYLETHYL [(1S)-1-CARBAMOYL)PYRROLIDIN-1-YL]CARBONYL}-2,2-DIMETHYLPROPYL]CARBAMATE

    The present disclosure includes various embodiments directed to a solubilized capsule formulation of asunaprevir, 1,1-dimethylethyl[(1S)-1-{[(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-ylox- y)-2-({(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}car- bamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate, and to methods including asunaprevir.

  • Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

    The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.

  • STABILIZED FORMULATION COMPRISING OMEGA-3 FATTY ACIDS AND USE OF THE FATTY ACIDS FOR SKIN CARE AND/OR WOUND CARE

    A stabilized formulation for skin care, wound care and/or other tissue healing applications and methods for making the same is described. The stabilized formulation stabilizes omega-3 polyunsaturated fatty acids and is constituted of the omega-3 polyunsaturated fatty acids in combination with tocopherol (Vitamin E), ascorbic acid (Vitamin C), herb extract, and a fat-soluble antioxidant. Methods for making and using the stabilized formulation are also described.

  • LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF

    The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.

  • ANTIOXIDANT COMPOSITIONS FOR SOFT ORAL TISSUE AND METHODS OF FORMULATION AND USE THEREOF

    The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.

  • UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM INCORPORATING TASTE-MASKING COMPOSITIONS

    The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

  • DOSAGE FORM CONTAINING OXYCODONE AND NALOXONE

    The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as t.sub.max, C.sub.max, AUCt value, mean bowel function score and/or duration of analgesic efficacy.

  • CONTROLLED RELEASE FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS

    Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective amount of an opioid analgesic and a therapeutically effective amount of nonopioid analgesic. In a preferred embodiment, the nonopioid analgesic is acetaminophen and the opioid analgesic is hydrocodone and pharmaceutically acceptable salts thereof, and in preferred embodiments, the pharmaceutically acceptable salt is bitartrate. The dosage forms produce plasma profiles in a patient characterized by a Cmax for hydrocodone of between about 0.6 ng/mL/mg to about 1.4 ng/mL/mg and an AUC for hydrocodone of between about 9.1 ng*hr/mL/mg to about 19.9 ng*hr/mL/mg (per mg hydrocodone bitartrate administered) and a Cmax for acetaminophen of between about 2.8 ng/mL/mg and 7.9 ng/mL/mg and an AUC for acetaminophen of between about 28.6 ng*hr/mL/mg and about 59.1 ng*hr/mL/mg (per mg acetaminophen administered) after a single dose.

  • TAMPER RESISTANT DOSAGE FORMS

    The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

  • MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF

    The presently claimed and disclosed inventive concept(s) contemplates a novel polymeric oral dosage form (transmucosal delivery vehicle) for delivery of pharmaceutical and nutriceutical bioactive agents to the mucosa and bloodstream of the intestine. The oral dosage form of the presently claimed and disclosed inventive concept(s) comprises a polymeric coating which encapsulates the bioactive agent and inhibits degradation and dissolution of the bioactive agent within the stomach and within the lumen of the intestine until after passing through the mucosal wall of the small and/or large intestine. The enzymatic degradation of the polymeric delivery vehicle containing the bioactive agent is substantially inhibited until after absorption of the polymeric delivery vehicle into blood vessels of the intestinal mucosa. It is a particular object of the presently claimed and disclosed inventive concept(s) to provide a new and improved method for enterically or intestinally encapsulating pharmaceutical and nutriceutical bioactive agent or agents for oral administration of the encapsulated bioactive agent or agents.

  • jetwave test

    dummy data